首页 > 最新文献

The open prostate cancer journal最新文献

英文 中文
The roles of homeobox genes in prostate cancer 同型盒基因在前列腺癌中的作用
Pub Date : 1999-03-01 DOI: 10.1046/J.1525-1411.1999.09910.X
A. Gao
{"title":"The roles of homeobox genes in prostate cancer","authors":"A. Gao","doi":"10.1046/J.1525-1411.1999.09910.X","DOIUrl":"https://doi.org/10.1046/J.1525-1411.1999.09910.X","url":null,"abstract":"","PeriodicalId":22947,"journal":{"name":"The open prostate cancer journal","volume":"62 1","pages":"61-67"},"PeriodicalIF":0.0,"publicationDate":"1999-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89598226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Do Calcium Channel Blockers Adversely Affect Hormonal Treatment of Prostate Cancer Through an Inhibition of Apoptosis 钙通道阻滞剂是否通过抑制细胞凋亡对激素治疗前列腺癌产生不利影响
Pub Date : 1999-01-01 DOI: 10.1046/J.1525-1411.1999.00004.X
T. Buchholz, Y. Tony, Douglas Martin, C. R. Powell, P. Johnstone, P. Allen
Background: Hormonal therapy of prostate cancer is mediated, in part, through apoptosis. This process is dependent on intracellular calcium influx. This study investigates whether the use of calcium channel blockers inhibits this process and thereby negatively impacts hormonal therapy. Methods: Records from patients dying from metastatic prostate cancer in three medical centers were reviewed. The date of diagnosis, date of metastatic disease, date of death, Gleason sum, type of hormone therapy, and calcium channel blocker used were recorded. Results: Of the 180 patients, 26 were on a calcium channel blocker at the time of their hormonal therapy. The length of survival from the time of hormone therapy to death in these patients did not differ from the 154 patients not on a calcium channel blocker (respective median survival time of 819 days versus 730 days, p = 0.913—log rank test of the survival curves). Similarly, there were no differences in length of survival from the date of diagnosis between the two groups. Other analyzed factors (type of hormone therapy, Gleason score, and interval between diagnosis and metastatic disease) also did not affect length of survival from the time of hormonal treatment or time of diagnosis. Conclusion: We found no evidence that calcium channel blockers inhibit the therapeutic efficacy of hormonal treatment for metastatic prostate cancer.
背景:前列腺癌的激素治疗部分是通过细胞凋亡介导的。这一过程依赖于细胞内钙的流入。本研究探讨钙通道阻滞剂的使用是否会抑制这一过程,从而对激素治疗产生负面影响。方法:回顾三家医疗中心转移性前列腺癌死亡患者的记录。记录诊断日期、转移性疾病日期、死亡日期、格里森总和、激素治疗类型和使用的钙通道阻滞剂。结果:在180例患者中,26例在激素治疗时使用钙通道阻滞剂。这些患者从激素治疗到死亡的生存时间与154名未使用钙通道阻滞剂的患者没有差异(各自的中位生存时间分别为819天对730天,p = 0.913-log生存曲线秩检验)。同样,自诊断之日起,两组之间的生存时间也没有差异。其他分析的因素(激素治疗类型、Gleason评分、诊断与转移性疾病之间的间隔)也不影响从激素治疗时间或诊断时间算起的生存时间。结论:没有证据表明钙通道阻滞剂会抑制激素治疗转移性前列腺癌的疗效。
{"title":"Do Calcium Channel Blockers Adversely Affect Hormonal Treatment of Prostate Cancer Through an Inhibition of Apoptosis","authors":"T. Buchholz, Y. Tony, Douglas Martin, C. R. Powell, P. Johnstone, P. Allen","doi":"10.1046/J.1525-1411.1999.00004.X","DOIUrl":"https://doi.org/10.1046/J.1525-1411.1999.00004.X","url":null,"abstract":"Background: Hormonal therapy of prostate cancer is mediated, in part, through apoptosis. This process is dependent on intracellular calcium influx. This study investigates whether the use of calcium channel blockers inhibits this process and thereby negatively impacts hormonal therapy. Methods: Records from patients dying from metastatic prostate cancer in three medical centers were reviewed. The date of diagnosis, date of metastatic disease, date of death, Gleason sum, type of hormone therapy, and calcium channel blocker used were recorded. Results: Of the 180 patients, 26 were on a calcium channel blocker at the time of their hormonal therapy. The length of survival from the time of hormone therapy to death in these patients did not differ from the 154 patients not on a calcium channel blocker (respective median survival time of 819 days versus 730 days, p = 0.913—log rank test of the survival curves). Similarly, there were no differences in length of survival from the date of diagnosis between the two groups. Other analyzed factors (type of hormone therapy, Gleason score, and interval between diagnosis and metastatic disease) also did not affect length of survival from the time of hormonal treatment or time of diagnosis. Conclusion: We found no evidence that calcium channel blockers inhibit the therapeutic efficacy of hormonal treatment for metastatic prostate cancer.","PeriodicalId":22947,"journal":{"name":"The open prostate cancer journal","volume":"279 1","pages":"43-48"},"PeriodicalIF":0.0,"publicationDate":"1999-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86736467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neutron Radiation for Prostate Cancer 中子辐射治疗前列腺癌
Pub Date : 1999-01-01 DOI: 10.1046/J.1525-1411.1999.00003.X
J. Forman
{"title":"Neutron Radiation for Prostate Cancer","authors":"J. Forman","doi":"10.1046/J.1525-1411.1999.00003.X","DOIUrl":"https://doi.org/10.1046/J.1525-1411.1999.00003.X","url":null,"abstract":"","PeriodicalId":22947,"journal":{"name":"The open prostate cancer journal","volume":"16 1","pages":"8-14"},"PeriodicalIF":0.0,"publicationDate":"1999-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86858290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Incidental Carcinoma of the Prostate in the PSA Era PSA时代偶发性前列腺癌
Pub Date : 1999-01-01 DOI: 10.1046/J.1525-1411.1999.00002.X
L. Galejs, J. Hollander
Background: Prostate cancer has classically been discovered in 10% of prostatectomy specimens from presumed benign disease. Our objective was to review incidental cancer in transurethral prostatectomy (TURP) specimens and to establish whether or not the incidence, presentation, and pathology have changed since the advent of prostate specific antigen (PSA). Methods: Five hundred and thirty patients underwent TURP for presumed benign disease at our institution in 1985 (before PSA), and 481 underwent TURP between 1994 and 1995. The charts of all patients with cancer were reviewed. Patients with known cancer preoperatively were excluded. Charts were reviewed with regard to indication for TURP, presentation, age, size of prostate, digital rectal exam, PSA, and pathology report. The most recent preoperative PSA value was utilized. Pathologic factors included the weight (grams resected), grade, and extent of tumors. Stage T1a tumors were defined as having Gleason scores of <6 and volumes of <5%. If the percentage of volume was not given, the specimen was considered to be Stage T1a if cancer was present in three chips or less. All other tumors were considered Stage T1b disease. Results: In 1985, Stage T1a cancer comprised 4% of specimens, and Stage T1b comprised 6%. In 1994 and 1995, Stage T1a cancer comprised 4%, but Stage T1b comprised 3%. This change in the incidence of T1b disease was statistically significant with a p value of 0.04. There was no difference with regard to patient age, specimen weight, or Gleason score. Urinary retention was a more common indication for TURP in 1994 and 1995. Conclusions: Our findings suggest that PSA screening has decreased the incidence of Stage T1b prostate cancer.
背景:前列腺癌通常在10%推定为良性疾病的前列腺切除术标本中被发现。我们的目的是回顾经尿道前列腺切除术(TURP)标本中的偶发癌,并确定自前列腺特异性抗原(PSA)出现以来,其发生率、表现和病理是否发生了变化。方法:1985年(PSA出现前),530例患者在本院接受了推测为良性疾病的TURP治疗;1994 - 1995年间,481例患者接受了TURP治疗。回顾了所有癌症患者的图表。排除术前已知癌症的患者。我们回顾了关于TURP的适应症、表现、年龄、前列腺大小、直肠指检、PSA和病理报告的图表。使用最新的术前PSA值。病理因素包括肿瘤的重量(切除的克数)、分级和范围。T1a期肿瘤定义为Gleason评分<6,体积<5%。如果没有给出体积百分比,如果肿瘤出现在三个或更少的芯片中,则认为标本为T1a期。所有其他肿瘤被认为是T1b期疾病。结果:1985年,T1a期癌症占标本的4%,T1b期占6%。1994年和1995年,T1a期癌症占4%,但T1b期占3%。T1b发病率的变化有统计学意义,p值为0.04。在患者年龄、标本重量或Gleason评分方面没有差异。尿潴留是1994年和1995年TURP更常见的指征。结论:我们的研究结果表明,PSA筛查降低了T1b期前列腺癌的发病率。
{"title":"Incidental Carcinoma of the Prostate in the PSA Era","authors":"L. Galejs, J. Hollander","doi":"10.1046/J.1525-1411.1999.00002.X","DOIUrl":"https://doi.org/10.1046/J.1525-1411.1999.00002.X","url":null,"abstract":"Background: Prostate cancer has classically been discovered in 10% of prostatectomy specimens from presumed benign disease. Our objective was to review incidental cancer in transurethral prostatectomy (TURP) specimens and to establish whether or not the incidence, presentation, and pathology have changed since the advent of prostate specific antigen (PSA). Methods: Five hundred and thirty patients underwent TURP for presumed benign disease at our institution in 1985 (before PSA), and 481 underwent TURP between 1994 and 1995. The charts of all patients with cancer were reviewed. Patients with known cancer preoperatively were excluded. Charts were reviewed with regard to indication for TURP, presentation, age, size of prostate, digital rectal exam, PSA, and pathology report. The most recent preoperative PSA value was utilized. Pathologic factors included the weight (grams resected), grade, and extent of tumors. Stage T1a tumors were defined as having Gleason scores of <6 and volumes of <5%. If the percentage of volume was not given, the specimen was considered to be Stage T1a if cancer was present in three chips or less. All other tumors were considered Stage T1b disease. Results: In 1985, Stage T1a cancer comprised 4% of specimens, and Stage T1b comprised 6%. In 1994 and 1995, Stage T1a cancer comprised 4%, but Stage T1b comprised 3%. This change in the incidence of T1b disease was statistically significant with a p value of 0.04. There was no difference with regard to patient age, specimen weight, or Gleason score. Urinary retention was a more common indication for TURP in 1994 and 1995. Conclusions: Our findings suggest that PSA screening has decreased the incidence of Stage T1b prostate cancer.","PeriodicalId":22947,"journal":{"name":"The open prostate cancer journal","volume":"74 1","pages":"27-31"},"PeriodicalIF":0.0,"publicationDate":"1999-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75837351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Postprostatectomy External Beam Irradiation 前列腺切除术后外束照射
Pub Date : 1900-01-01 DOI: 10.1046/J.1525-1411.1999.00005.X
I. Kaplan, M. Jiroutek, D. Henry, C. Beard, A. D'Amico
Background: A significant proportion of patients will be found to have extracapsular disease and/or detectable prostate specific antigen (PSA) values after radical prostatectomy. The role of postoperative radiotherapy to the prostatic tumor bed remains controversial. Methods: Ninety patients were treated at the Joint Center for Radiation Therapy after radical prostatectomy. The medium dose to prostatic fossa was 64.0 Gy. Medium follow-up was 28.9 months (from time of prostatectomy). Failure after radiotherapy is defined as a persistently detectable PSA level or the development of a detectable PSA level after radiotherapy. None of the patients received androgen ablative therapy until documented postradiotherapy failure. Presurgical PSA levels, Gleason score, pathological findings at surgery, and preradiotherapy PSA levels were analyzed as predictors of PSA failure. Results: A presurgical PSA of >20.0 ng/ml is associated with PSA failure after radiotherapy (p = 0.0239). Preoperative Gleason score, PSA at time of radiotherapy or pathological findings at surgery do not predict for subsequent PSA failure. Conclusion: Postprostatectomy radiotherapy to the prostatic fossa is unlikely to provide long-term PSA-defined, disease-free survival for patients who undergo prostatectomy with a presurgical PSA of >20 ng/ml. Regardless of findings at surgery, these patients have a high rate of developing PSA failure.
背景:相当比例的患者在根治性前列腺切除术后会发现有囊外疾病和/或可检测到前列腺特异性抗原(PSA)值。前列腺肿瘤床术后放射治疗的作用仍有争议。方法:90例根治性前列腺切除术后患者在联合放射治疗中心接受治疗。前列腺窝的中剂量为64.0 Gy。中期随访28.9个月(从前列腺切除术开始)。放疗失败定义为持续可检测的PSA水平或放疗后PSA水平的发展。没有患者接受雄激素消融治疗,直到记录后治疗失败。分析术前PSA水平、Gleason评分、手术病理结果和放疗前PSA水平作为PSA失败的预测因子。结果:术前PSA >20.0 ng/ml与放疗后PSA失败相关(p = 0.0239)。术前Gleason评分、放疗时的PSA或手术时的病理结果不能预测随后的PSA失败。结论:对于术前PSA >20 ng/ml的前列腺切除术患者,前列腺切除术后对前列腺窝进行放疗不太可能提供长期PSA定义的无病生存。无论手术结果如何,这些患者的PSA失败率很高。
{"title":"Postprostatectomy External Beam Irradiation","authors":"I. Kaplan, M. Jiroutek, D. Henry, C. Beard, A. D'Amico","doi":"10.1046/J.1525-1411.1999.00005.X","DOIUrl":"https://doi.org/10.1046/J.1525-1411.1999.00005.X","url":null,"abstract":"Background: A significant proportion of patients will be found to have extracapsular disease and/or detectable prostate specific antigen (PSA) values after radical prostatectomy. The role of postoperative radiotherapy to the prostatic tumor bed remains controversial. \u0000 \u0000 \u0000 \u0000Methods: Ninety patients were treated at the Joint Center for Radiation Therapy after radical prostatectomy. The medium dose to prostatic fossa was 64.0 Gy. Medium follow-up was 28.9 months (from time of prostatectomy). Failure after radiotherapy is defined as a persistently detectable PSA level or the development of a detectable PSA level after radiotherapy. None of the patients received androgen ablative therapy until documented postradiotherapy failure. Presurgical PSA levels, Gleason score, pathological findings at surgery, and preradiotherapy PSA levels were analyzed as predictors of PSA failure. \u0000 \u0000 \u0000 \u0000Results: A presurgical PSA of >20.0 ng/ml is associated with PSA failure after radiotherapy (p = 0.0239). Preoperative Gleason score, PSA at time of radiotherapy or pathological findings at surgery do not predict for subsequent PSA failure. \u0000 \u0000 \u0000 \u0000Conclusion: Postprostatectomy radiotherapy to the prostatic fossa is unlikely to provide long-term PSA-defined, disease-free survival for patients who undergo prostatectomy with a presurgical PSA of >20 ng/ml. Regardless of findings at surgery, these patients have a high rate of developing PSA failure.","PeriodicalId":22947,"journal":{"name":"The open prostate cancer journal","volume":"11 1","pages":"32-37"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88732238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
The open prostate cancer journal
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1